Page 2 - Robert Iannone News Today

LONDON, June 20, 2023 -- Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that Dr. Robert Iannone,... | June 20, 2023

Operator: Good day, and thank you for standing by. Welcome to the Q1 2023 Jazz Pharmaceuticals Earnings Conference Call. [Operator Instructions].

Jazz announced on Monday that the U.S. Food and Drug Administration granted them Orphan Drug Exclusivity for the medication Xywav.

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Exclusivity...

ODE for IH for adults follows June 2021 grant of ODE for treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy DUBLIN, Jan. 3, 2022 /PRNewswire/

Data from six abstracts advancing cannabidiol (CBD) research to be presented, including two abstracts which highlight results from a U.S. caregiver survey that provides insight on real-world

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations,...

Sixteen new abstracts to be presented, including the first presentation of data from the Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 study that supported U.S. FDA

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will...

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will...